Neuroprotection by silencing iNOS expression in a 6-OHDA model of Parkinson's disease

Journal of Molecular Neuroscience

Volumn 48, Issue 1, 2012, Pages 225-233

  Li, Min ^a   Dai, Fu Rong ^a   Du, Xiao Ping ^a   Yang, Qi Dong ^a   Chen, Yuxiang ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Bax; Caspase 3; Microglia; P53; Striatum; TH

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; APOMORPHINE; BRAIN PROTEIN; CASPASE 3; DOPAMINE; HOMOVANILLIC ACID; OX 42 PROTEIN; OXIDOPAMINE; PROTEIN BAX; PROTEIN P53; SMALL INTERFERING RNA; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; INDUCIBLE NITRIC OXIDE SYNTHASE GENE; MALE; MICROGLIA; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SUBSTANTIA NIGRA; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; APOPTOSIS; CELL LINE; CORPUS STRIATUM; DOPAMINERGIC NEURONS; HUMANS; KIDNEY; MACROPHAGES; MALE; MICE; MICROGLIA; MOTOR ACTIVITY; NITRIC OXIDE SYNTHASE TYPE II; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; RNA, SMALL INTERFERING; SYMPATHOLYTICS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865122074     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-012-9814-5     Document Type: Article

References (29)

1. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL (2009) Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys 486:95-102
2. Barthwal MK, Srivastava N, Dikshit M (2001) Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat. Redox Rep 6:297-302 (Pubitemid 33094661)
3. Ben-Shachar D, Youdim MB (1991) Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J Neurochem 57:2133-2135 (Pubitemid 21922868)
4. Blandini F, Levandis G, Bazzini E, Nappi G, Armentero MT (2007) Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. Eur J Neurosci 25:397-405
5. Blandini F, Armentero MT, Martignoni E (2008) The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 14:S124-129
6. Broom L, Marinova-Mutafchieva L, Sadeghian M, Davis JB, Medhurst AD, Dexter DT (2011) Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease. Free Radic Biol Med 50:633-640
7. Chao OY, Huston JP, von Bothmer A, Pum ME (2011) Chronic progesterone treatment of male rats with unilateral 6-hydroxydopamine lesion of the dorsal striatum exasperates parkinsonian symptoms. Neuroscience 196:228-236
8. Coelln RV, Kugler S, Bahr M, Weller M, Dichgans J, Schulz JB (2001) Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. J Neurochem 77:263-273 (Pubitemid 32245100)
9. Conti A, Miscusi M, Cardali S, Germanò A, Suzuki H, Cuzzocrea S, Tomasello F (2007) Nitric oxide in the injured spinal cord: synthases cross-talk, oxidative stress and inflammation. Brain Res Rev 54:205-218 (Pubitemid 46498169)
10. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889-909 (Pubitemid 37130207)
11. Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB (2000) Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 74:2213-2216 (Pubitemid 30217680)
12. Deumens R, Blokland A, Prickaerts J (2002) Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175:303-317 (Pubitemid 34634286)
13. Hague S, Peuralinna T, Eerola J, Hellström O, Tienari PJ, Singleton AB (2004) Confirmation of the protective effect of iNOS in an independent cohort of Parkinson disease. Neurology 62:635-6 (Pubitemid 38252810)
14. Hald A, Lotharius J (2005) Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol 193:279-290 (Pubitemid 40616179)
15. Han BS, Hong HS, Choi WS, Markelonis GJ, Oh TH, Oh YJ (2003) Caspase-dependent and -independent cell death pathways in primary cultures of mesencephalic dopaminergic neurons after neurotoxin treatment. J Neurosci 23:5069-5078 (Pubitemid 36793234)
16. Hoang T, Choi DK, Nagai M, Wu DC, Nagata T, Prou D, Wilson GL, Vila M, Jackson-Lewis V, Dawson VL, Dawson TM, Chesselet MF, Przedborski S (2009) Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radic Biol Med 47:1049-1056
17. Holtz WA, Turetzky JM, Jong YJ, O'Malley KL (2006) Oxidative stress-triggered unfolded protein response is upstream of intrinsic cell death evoked by parkinsonian mimetics. J Neurochem 99:54-69 (Pubitemid 44395130)
18. Holtz WA, O'Malley KL (2003) Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J Biol Chem 278:19367-19377 (Pubitemid 36799332)
19. Hunot S, Boissière F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72:355-363 (Pubitemid 26111202)
20. Iravani MM, Kashefi K, Mander P, Rose S, Jenner P (2002) Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110:49-58 (Pubitemid 34214759)
21. Knott C, Stern G, Wilkin GP (2000) Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 16:724-739 (Pubitemid 32062060)
22. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5:1403-1409
23. Liu B, Gao HM, Hong JS (2003) Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 111:1065-1073 (Pubitemid 36826886)
24. Possel H, Noack H, Putzke J, Wolf G, Sies H (2000) Selective upregulation of inducible nitric oxide synthase (iNOS) by lipopolysaccharide (LPS) and cytokines in microglia: in vitro and in vivo studies. Glia 32:51-59
25. Okuno T, Nakatsuji Y, Kumanogoh A, Moriya M, Ichinose H, Sumi H, Fujimura H, Kikutani H, Sakoda S (2005) Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD 40: relevance to Parkinson's disease. J Neurosci Res 81:874-882 (Pubitemid 41532153)
26. O'Malley KL, Liu J, Lotharius J, Holtz W (2003) Targeted expression of BCL-2 attenuates MPP + but not 6-OHDA induced cell death in dopaminergic neurons. Neurobiol Dis 14:43-51 (Pubitemid 37103178)
27. Rodrigues RW, Gomide VC, Chadi G (2001) Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine. Int J Neurosci 109:91-126 (Pubitemid 32832158)
28. Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates, 6th edn. Academic, San Diego
29. Tieu K, Ischiropoulos H, Przedborski S (2003) Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life 55:329-335 (Pubitemid 36975543)